{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-003052","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.861050+00:00","generated_at":"2026-05-14T23:05:17.150665+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCryst Q1 ORLADEYO rev $148.3M (+11% YoY); non-GAAP op profit $54.2M; licenses EU navenibart rights for $70M upfront","bullets":["ORLADEYO net revenue $148.3M, +11% reported, +21% ex-Europe; GAAP operating loss $701.6M includes $697.8M non-cash IPR&D charge from Astria acquisition.","Non-GAAP operating profit of $54.2M; guidance reaffirmed: FY2026 ORLADEYO rev $625-645M, total rev $635-660M, op ex $450-470M.","Licensed European navenibart rights to Neopharmed Gentili for $70M upfront, up to $275M milestones, plus 18-30% royalties.","Navenibart pivotal study ALPHA-ORBIT enrollment on track to complete by June 2026; US regulatory filing targeted by end 2027.","Appointed Sandeep Menon as Chief R&D Officer in April; ended avoralstat DME program to focus on rare diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-003052","json":"https://secwatch.observer/filing/0001171843-26-003052.json","markdown":"https://secwatch.observer/filing/0001171843-26-003052.md","text":"https://secwatch.observer/filing/0001171843-26-003052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/0001171843-26-003052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/f8k_050626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:05:17.150665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5da7e6f356977b09e0b9ce68538599cb6307dc59","claim":"BIOCRYST PHARMACEUTICALS INC updated its the quarter ended March 31, 2026 guidance (reaffirmed).","evidence_excerpt":"BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended March 31, 2026, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/0001171843-26-003052-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}